Amunix: Cancer drug maker lands $1.2 billion Big Pharma deal

The same protein-engineering technology Amunix Pharmaceuticals Inc. CEO Angie You hoped to harness for a portfolio of cancer drugs will become part of French drug company Sanofi SA as part of a potential $1.2 billion acquisition. Sanofi (NASDAQ: SNY) will pay about $1 billion upfront and up to $225 million in development milestones to buy Amunix, the companies said Tuesday. The deal is expected to be completed in first-quarter 2022. You joined Amunix as CEO nearly three years ago, charged with...